THE ROLE OF DYSLIPIDEMIA IN THE PROGRESSION OF DIABETIC RETINOPATHY
https://doi.org/10.21518/2079-701X-2017-3-44-46
Abstract
Angiogenesis factors, growth factors (vascular endothelial growth factor (VEGF), angiopoietin-2, insulin-like growth factor, etc.) and cytokines play the leading role in the production by endothelial cells of new retinal blood vessels, increased vascular permeability resulting in exudation and macular edema leading to the development of irreversible complications and vision loss. Although large-scale clinical trials demonstrated that tight control of glycemia and normalization of systemic blood pressure reduce the risk of progression of diabetic retinopathy (DR), the relationship between lipid disorders and retinal damage is not fully understood.
About the Authors
A. G. Kuzmin
Endocrinological Scientific Centre
Russian Federation
Russian Federation
PhD in Medicine,
Moscow
S. A. Martynov
Endocrinological Scientific Centre
Russian Federation
Russian Federation
PhD in Medicine,
Moscow
M. V. Shestakova
Endocrinological Scientific Centre
Russian Federation
Russian Federation
MD, Prof., academician of the RAS,
Moscow
References
1. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology, 1991, 98(8): 1261–1265.
2. Chew E.Y., Klein M.L., Ferris F.L. et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol, 1996, 114(9): 1079–1084.
3. Miljanovic B, Glynn RJ, Nathan DM et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes, 2004, 53(11): 2883–2892.
4. Rema M, Srivastava BK, Anitha B at al. Association of serum lipids with diabetic retinopathy in urban South Indians – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med, 2006, 23(9): 1029–1036.
5. Smolders B, Lemmers R, Thijs V. Lipoprotein(a) and stroke: a meta-analysis of observational studies. Stroke, 2007, 38(6): 1959–1966.
6. Stitt AW, Frizzell N, Thorpe SR. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des, 2004, 10(27): 3349-3360.
7. Gordon B, Chang S, Kavanagh M et al. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol, 1991, 112(4): 385–391.
8. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract, 2002, 56(1): 1–11.
9. Wassmann S, Laufs U, Muller K et al. Сellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 2002, 22: 300–305.
10. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364(9435): 685–696.
11. Zhang J, McGwin GJ. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol, 2007 Aug, 125(8): 1096-1099.
12. Harrold BP, Marmion VJ, Gough KR. A doubleblind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes, 1969, 18(5): 285–291.
13. Duncan LJ, Cullen JF, Ireland JT et al. A threeyear trial of atromid therapy in exudative diabetic retinopathy. Diabetes, 1968, 17(7): 458–467.
14. Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK, 1994, 94(2): 554–562.
15. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet, 2007, 370(9600): 1687–1697.
16. Panigrahy D, Kaipainen A, Huang S et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A, 2008, 105: 985–990.
17. Meissner M, Stein M, Urbich C et al. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1- dependent DNA binding and transactivation. Circ Res, 2004, 94: 324–332.
18. Tomizawa A, Hattori Y, Inoue T et al. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism, 2011, 60: 513–522.
19. Marx N, Sukhova GK, Collins T et al. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99: 3125–3131.
20. Ibarra-Lara L, Hong E, Soria-Castro E et al. Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. J Cardiovasc Pharmacol, 2012, 60: 323–334.
21. Chew EY, Ambrosius WT, Davis MD et al. ACCORD Study Group. ACCORD Eye Study GroupEffects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363: 233–244.
22. Morton J, Zoungas S, Li Q et al. ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care, 2012, 35(11): 2201–2206.
23. Ibrahim AS, Tawfik AM, Hussein KA et al. Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids. Biochim Biophys Acta, 2015, 1851(3): 290-298.
24. Ibrahim AS, Elshafey S, Sellak H et al. A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. J Lipid Res, 2015, 56(3): 599-611.
25. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res, 2005, 24(1): 87-138.
Review
For citations:
Kuzmin AG, Martynov SA, Shestakova MV. THE ROLE OF DYSLIPIDEMIA IN THE PROGRESSION OF DIABETIC RETINOPATHY. Meditsinskiy sovet = Medical Council. 2017;(3):44-46. (In Russ.) https://doi.org/10.21518/2079-701X-2017-3-44-46
Views:
541
Email this article 